Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal

Sees Potential Beyond Vaccines

Executive Summary

VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.

You may also be interested in...



Moderna Makes Major mRNA Commitment To UK

The US biotech major has unveiled plans to open a new research and manufacturing center in the UK, which signals the start of detailed talks with the government about establishing a long-term partnership.

Providence’s COVID-19 mRNA Vaccine Challenger Seen In Phase III In Q1

A possible alternative to Pfizer and Moderna’s COVID-19 vaccines, Providence Therapeutics’ mRNA candidate is seen moving into Phase III trials during the calendar first quarter of next year. While partners Everest Medicines and Biological E have kept the ball rolling, the Canadian biotech will seek further funding, CEO Brad Sorenson tells Scrip in this audio interview.

Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy

The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.

AstraZeneca is moving into the field of self-amplifying RNA via a deal with VaxEquity, with the goal of developing a next generation vaccines and therapeutics platform more potent than the Pfizer/BioNTech and Moderna pioneering messenger RNA (mRNA) vaccines.

The new partners have their sights set on a broad range of potential vaccine and therapeutic targets, with AstraZeneca seeing the pact as an addition to its broader R&D toolbox.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel